NCT01449513View on ClinicalTrials.gov

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Actinic Keratosis
Interventions
DRUG

Ingenol mebutate

0.05% Ingenol mebutate Gel once daily for 2 consecutive days

DRUG

Placebo Gel

Gel vehicle of PEP005

Trial Locations (1)

10117

Charité - Universitätsmedizin Berlin, Berlin

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY